JP7818514B2 - タンパク質を搭載したｐｌｇａナノスフィア - Google Patents

タンパク質を搭載したｐｌｇａナノスフィア

Info

Publication number
JP7818514B2
JP7818514B2 JP2022534255A JP2022534255A JP7818514B2 JP 7818514 B2 JP7818514 B2 JP 7818514B2 JP 2022534255 A JP2022534255 A JP 2022534255A JP 2022534255 A JP2022534255 A JP 2022534255A JP 7818514 B2 JP7818514 B2 JP 7818514B2
Authority
JP
Japan
Prior art keywords
nanospheres
emulsion
plga
cytokine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504282A (ja
JP2023504282A5 (https=
Inventor
ブロック エー． リンジー，
ジャスティン イー． マーケル，
ライアン エー． ラチンスキ，
ジャビーン ノーア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Virginia University filed Critical West Virginia University
Publication of JP2023504282A publication Critical patent/JP2023504282A/ja
Publication of JP2023504282A5 publication Critical patent/JP2023504282A5/ja
Application granted granted Critical
Publication of JP7818514B2 publication Critical patent/JP7818514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022534255A 2019-12-05 2020-12-04 タンパク質を搭載したｐｌｇａナノスフィア Active JP7818514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944191P 2019-12-05 2019-12-05
US62/944,191 2019-12-05
PCT/US2020/063314 WO2021113638A1 (en) 2019-12-05 2020-12-04 Protein-loaded plga nanospheres

Publications (3)

Publication Number Publication Date
JP2023504282A JP2023504282A (ja) 2023-02-02
JP2023504282A5 JP2023504282A5 (https=) 2023-12-12
JP7818514B2 true JP7818514B2 (ja) 2026-02-20

Family

ID=76221229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534255A Active JP7818514B2 (ja) 2019-12-05 2020-12-04 タンパク質を搭載したｐｌｇａナノスフィア

Country Status (11)

Country Link
US (3) US12214046B2 (https=)
EP (1) EP4072536A4 (https=)
JP (1) JP7818514B2 (https=)
KR (1) KR20220143811A (https=)
CN (1) CN115335041A (https=)
AU (1) AU2020396557A1 (https=)
BR (1) BR112022010952A2 (https=)
CA (1) CA3160922A1 (https=)
IL (1) IL293607A (https=)
MX (1) MX2022006824A (https=)
WO (1) WO2021113638A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres
CN116855571B (zh) * 2023-06-26 2025-03-21 中国农业大学 Plga纳米球病毒示踪剂及其制备方法与应用
KR20250069077A (ko) * 2023-11-10 2025-05-19 아주대학교산학협력단 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120265001A1 (en) 2010-10-11 2012-10-18 Wichita State University Composite magnetic nanoparticle drug delivery system
JP2014527980A (ja) 2011-09-21 2014-10-23 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． ナノ送達システム
WO2019162951A1 (en) 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20040003402A1 (en) 2002-06-27 2004-01-01 Digeo, Inc. Method and apparatus for automatic ticker generation based on implicit or explicit profiling
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
WO2007074604A1 (ja) 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
EP2251006B1 (en) 2008-02-22 2017-07-19 Toray Industries, Inc. Microparticles and pharmaceutical compositions thereof
US9972047B1 (en) 2008-04-18 2018-05-15 Capital One Services, Llc Systems and methods for performing a purchase transaction using rewards points
US20090281888A1 (en) 2008-05-09 2009-11-12 Li-Cheng Richard Zai Method And Apparatus For Establishing Time-Based Loyalty Relationship
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
WO2011063177A1 (en) 2009-11-20 2011-05-26 Mobisave Corporation System and method of electronically verifying required proof-of-performance to secure promotional rewards
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CA2869748C (en) * 2012-04-12 2017-10-24 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
US9724304B2 (en) 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
US9308172B2 (en) 2012-10-26 2016-04-12 Board Of Trustees Of Michigan State University Device and method for encapsulation of hydrophilic materials
CA2929277C (en) * 2013-11-01 2018-01-16 Yale University Delivery vehicles comprising il-2 and losartan
WO2016061201A1 (en) * 2014-10-14 2016-04-21 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
CN104622795B (zh) * 2015-01-28 2017-12-08 杭州市萧山区中医院 一种多细胞因子序贯缓释微球‑水凝胶复合系统及其制备方法
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
EP3987054A4 (en) 2019-06-18 2023-06-14 Biomeme Incorporated SAMPLE ANALYSIS SYSTEMS
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120265001A1 (en) 2010-10-11 2012-10-18 Wichita State University Composite magnetic nanoparticle drug delivery system
JP2014527980A (ja) 2011-09-21 2014-10-23 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． ナノ送達システム
WO2019162951A1 (en) 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRAYTHORNE,N.L. et al，Stabilisation of W/O/W nanoemulsions through the use of stabilising agents poly(vinyl alcohol) and nonionic surfactants tween 20 and Span 80，Journal of Pharmacy and Pharmaceutical Sciences，2011年，Vol.14, No.3，p.216s-217s
Mohsen ASHJARI et al.，"Controlling the morphology and surface property of magnetic/cisplatin-loaded nanocapsules via W/O/W double emulsion method"，Colloids and Surfaces A: Physicochemical and Engineering Aspects，2012年08月，Vol. 408，p.87-96，DOI: 10.1016/j.colsurfa.2012.05.035
Reyhaneh VARSHOCHIAN et al.，"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment"，Journal of Biomedical Materials Research Part A，2015年03月27日，Vol. 103, No. 10，p.3148-3156，DOI: 10.1002/jbm.a.35446

Also Published As

Publication number Publication date
JP2023504282A (ja) 2023-02-02
US20250064949A1 (en) 2025-02-27
CN115335041A (zh) 2022-11-11
US20250073343A1 (en) 2025-03-06
EP4072536A4 (en) 2025-01-15
US20230070180A1 (en) 2023-03-09
IL293607A (en) 2022-08-01
AU2020396557A1 (en) 2022-06-23
EP4072536A1 (en) 2022-10-19
CA3160922A1 (en) 2021-06-10
WO2021113638A1 (en) 2021-06-10
BR112022010952A2 (pt) 2022-09-06
MX2022006824A (es) 2022-09-19
KR20220143811A (ko) 2022-10-25
US12214046B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US20250064949A1 (en) Protein-loaded plga nanospheres
JP5579586B2 (ja) 腫瘍ワクチン
US6193970B1 (en) Controlled release of pharmaceutically active substances for immunotherapy
CN103857387B (zh) 膜包封的纳米颗粒及使用方法
US10987314B2 (en) Antigen-specific, tolerance-inducing microparticles and uses thereof
CN112569207A (zh) 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
Jahan et al. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
CN111184684B (zh) 一种红细胞凝胶递释系统及其制备方法与应用
Yazdani et al. Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems
WO2018047797A1 (ja) 免疫刺激剤
Lacinski et al. Synthesis, characterization, and in vivo cytokinome profile of IL‐12‐loaded PLGA nanospheres
CN117899205A (zh) 一种基于凋亡红细胞膜的耐受性疫苗、制备方法及其应用
JP2023504282A5 (https=)
WO2019057113A1 (en) CAPECITABINE POLYMER-LIPID HYBRID NANOPARTICLES USING MICROMELIN AND AMPHIPHILIC CAPECITABINE PROPERTIES
HK40083735A (en) Protein-loaded plga nanospheres
WO2014034669A1 (ja) 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
JP4688254B2 (ja) 腫瘍ワクチン
JP3492671B2 (ja) 免疫アジュバント
CA2890258C (en) Composition comprising cytokine macro-aggregates
RU2753018C1 (ru) Наноструктурированная композиция для пероральной доставки инсулина и способ ее получения
CN119185522A (zh) 一种载细菌全抗原的plga微球疫苗及其制备方法与应用
CN119700999A (zh) 一种免疫检查点抑制剂及其制备方法和应用
JPWO2004087208A1 (ja) 熱ショックタンパク質と磁性微粒子からなる悪性腫瘍の温熱治療剤
CN115813850A (zh) 一种tam重编程抗癌凝胶及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260209

R150 Certificate of patent or registration of utility model

Ref document number: 7818514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150